JP2023550428A - インテグリン阻害剤およびその使用 - Google Patents

インテグリン阻害剤およびその使用 Download PDF

Info

Publication number
JP2023550428A
JP2023550428A JP2023530225A JP2023530225A JP2023550428A JP 2023550428 A JP2023550428 A JP 2023550428A JP 2023530225 A JP2023530225 A JP 2023530225A JP 2023530225 A JP2023530225 A JP 2023530225A JP 2023550428 A JP2023550428 A JP 2023550428A
Authority
JP
Japan
Prior art keywords
crystalline
approximately
weight
crystalline body
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023530225A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550428A5 (enExample
Inventor
チャ，ジェイコブ
レフテリス，カテリーナ
チー，ガオ
ワン，ジアン
ジャオ，ダリアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pliant Therapeutics Inc
Original Assignee
Pliant Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliant Therapeutics Inc filed Critical Pliant Therapeutics Inc
Publication of JP2023550428A publication Critical patent/JP2023550428A/ja
Publication of JP2023550428A5 publication Critical patent/JP2023550428A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2023530225A 2020-11-19 2021-11-19 インテグリン阻害剤およびその使用 Pending JP2023550428A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063116042P 2020-11-19 2020-11-19
US63/116,042 2020-11-19
PCT/US2021/072510 WO2022109598A1 (en) 2020-11-19 2021-11-19 Integrin inhibitor and uses thereof

Publications (2)

Publication Number Publication Date
JP2023550428A true JP2023550428A (ja) 2023-12-01
JP2023550428A5 JP2023550428A5 (enExample) 2024-11-26

Family

ID=81709878

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023530225A Pending JP2023550428A (ja) 2020-11-19 2021-11-19 インテグリン阻害剤およびその使用

Country Status (19)

Country Link
US (2) US12018025B2 (enExample)
EP (1) EP4247472A4 (enExample)
JP (1) JP2023550428A (enExample)
KR (1) KR20230121761A (enExample)
CN (1) CN116710169A (enExample)
AU (1) AU2021381516A1 (enExample)
CA (1) CA3173755A1 (enExample)
CL (1) CL2023001418A1 (enExample)
CO (1) CO2023006522A2 (enExample)
CR (1) CR20230262A (enExample)
CU (1) CU20230026A7 (enExample)
DO (1) DOP2023000101A (enExample)
EC (1) ECSP23045278A (enExample)
IL (1) IL302651A (enExample)
JO (1) JOP20230102A1 (enExample)
MX (1) MX2023005889A (enExample)
PE (1) PE20240114A1 (enExample)
TW (1) TW202235417A (enExample)
WO (1) WO2022109598A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
EP3952902A4 (en) 2019-04-08 2022-12-21 Pliant Therapeutics, Inc. DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS
TW202235417A (zh) 2020-11-19 2022-09-16 美商普萊恩醫療公司 整合素抑制劑及其用途
US20240122930A1 (en) * 2022-07-09 2024-04-18 Pliant Therapeutics, Inc. Integrin inhibitors and uses thereof in combination with other agents
WO2024155965A2 (en) * 2023-01-21 2024-07-25 Pliant Therapeutics, Inc. Biomarkers for use in integrin inhibitor therapy
US20250120975A1 (en) * 2023-09-25 2025-04-17 Pliant Therapeutics, Inc. Integrin inhibitors for treatment of primary sclerosing cholangitis
US20250197393A1 (en) 2023-12-14 2025-06-19 Pliant Therapeutics, Inc. Integrin inhibitor and uses thereof
WO2025217571A1 (en) * 2024-04-12 2025-10-16 Pliant Therapeutics, Inc. Fixed dose combinations of integrin inhibitor with ppar agonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019173653A1 (en) * 2018-03-07 2019-09-12 Pliant Therapeutics, Inc. Amino acid compounds and methods of use

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040105740A (ko) 2002-02-25 2004-12-16 엘란 파마슈티칼스, 인크. 염증 치료제의 투여 방법
ES2416354T3 (es) 2005-06-21 2013-07-31 Ajinomoto Co., Inc. Cristal de derivado de fenilalanina, método de producción del mismo y uso del mismo
WO2008045252A2 (en) 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
US8911952B2 (en) 2010-03-24 2014-12-16 Stc. Unm Method for integrin ligand discovery
MA37711A1 (fr) * 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
IN2015DN00099A (enExample) 2012-07-18 2015-05-29 Univ Saint Louis
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
EP3925959A1 (en) 2015-02-19 2021-12-22 OcuTerra Therapeutics, Inc. Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
AU2016228852A1 (en) 2015-03-10 2017-10-19 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
JP2018514568A (ja) 2015-04-30 2018-06-07 サイフルーア ライフ サイエンシズ インコーポレイテッド テトラヒドロナフチリジニルプロピオン酸誘導体およびその使用法
US10118929B2 (en) 2016-04-27 2018-11-06 Scifluor Life Sciences, Inc. Nonanoic and decanoic acid derivatives and uses thereof
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
EP4159727B1 (en) 2017-02-28 2026-04-08 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
WO2018183795A1 (en) 2017-03-30 2018-10-04 Scifluor Life Sciences, Inc. Method of making tetrahydronaphthyridinyl nonanoic acid compounds
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
JP7314135B2 (ja) * 2018-07-20 2023-07-25 株式会社半導体エネルギー研究所 撮像装置
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
EP3843728B1 (en) 2018-08-29 2025-04-30 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
AU2019327475B2 (en) 2018-08-29 2025-06-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
EP3903316A1 (en) * 2018-12-28 2021-11-03 LunaPBC Community data aggregation, completion, correction, and use
EP3923857B8 (en) * 2019-02-15 2024-04-17 Clean Bite, LLC Oral hygiene appliance
EP3952902A4 (en) * 2019-04-08 2022-12-21 Pliant Therapeutics, Inc. DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS
CN115151566A (zh) 2019-11-15 2022-10-04 普利安特治疗公司 用于活化整合素的组合物和方法
KR20230049584A (ko) * 2020-05-07 2023-04-13 플라이언트 테라퓨틱스, 인크. 아미노산 화합물을 사용한 호흡기 질환의 치료
TWI843503B (zh) * 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
TW202233224A (zh) * 2020-10-21 2022-09-01 美商寇峇有限公司 用組合療法治療纖維化之方法
TW202235417A (zh) 2020-11-19 2022-09-16 美商普萊恩醫療公司 整合素抑制劑及其用途
US20230028658A1 (en) 2021-04-30 2023-01-26 Pliant Therapeutics, Inc. Expanded dosage regimens for integrin inhibitors
US20240350494A1 (en) 2021-09-03 2024-10-24 Pliant Therapeutics, Inc. Therapeutic modulation of integrins
JP2024539645A (ja) 2021-10-14 2024-10-29 プライアント・セラピューティクス・インコーポレイテッド インテグリン阻害剤及び他の薬剤と組み合わせたその使用
WO2023225119A1 (en) 2022-05-18 2023-11-23 Pliant Therapeutics, Inc. Stabilization of integrin inhibitors
US20240122930A1 (en) 2022-07-09 2024-04-18 Pliant Therapeutics, Inc. Integrin inhibitors and uses thereof in combination with other agents
WO2024145245A2 (en) 2022-12-27 2024-07-04 Pliant Therapeutics, Inc. Alpha-v-beta-8 integrin inhibitors and uses thereof
WO2024155965A2 (en) 2023-01-21 2024-07-25 Pliant Therapeutics, Inc. Biomarkers for use in integrin inhibitor therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019173653A1 (en) * 2018-03-07 2019-09-12 Pliant Therapeutics, Inc. Amino acid compounds and methods of use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Ｃ．Ｇ．ＷＥＲＭＵＴＨ編, 最新 創薬化学 下巻, JPN6014029314, 1999, pages 347 - 365, ISSN: 0005770490 *
厚生省医薬安全局審査管理課長: "医薬品の残留溶媒ガイドラインについて", 医薬審, JPN6014031669, 1998, ISSN: 0005770488 *
平山令明, 有機化合物結晶作製ハンドブック, JPN6014035600, 2008, pages 17 - 23, ISSN: 0005770487 *
芦澤一英, 医薬品の多形現象と晶析の化学, JPN6015027444, 2002, pages 273 - 278, ISSN: 0005770489 *

Also Published As

Publication number Publication date
EP4247472A1 (en) 2023-09-27
MX2023005889A (es) 2023-06-06
US20220177468A1 (en) 2022-06-09
AU2021381516A9 (en) 2024-10-24
ECSP23045278A (es) 2023-07-31
DOP2023000101A (es) 2023-09-29
JOP20230102A1 (ar) 2023-05-08
CO2023006522A2 (es) 2023-06-09
CR20230262A (es) 2023-07-26
CN116710169A (zh) 2023-09-05
IL302651A (en) 2023-07-01
CA3173755A1 (en) 2022-05-27
US12018025B2 (en) 2024-06-25
PE20240114A1 (es) 2024-01-22
TW202235417A (zh) 2022-09-16
EP4247472A4 (en) 2024-10-09
AU2021381516A1 (en) 2023-06-22
CU20230026A7 (es) 2024-01-10
KR20230121761A (ko) 2023-08-21
WO2022109598A1 (en) 2022-05-27
US12637462B2 (en) 2026-05-26
US20240391914A1 (en) 2024-11-28
CL2023001418A1 (es) 2023-10-30

Similar Documents

Publication Publication Date Title
US20240391914A1 (en) Integrin inhibitor and uses thereof
ES3014022T3 (en) Angiotensin ii receptor antagonist metabolite and nep inhibitor composite, and preparation method thereof
CN110938042B (zh) 一种包含缬沙坦和ahu377的三钠盐超分子复合物的新晶型及其制备方法
JP5315253B2 (ja) ラセミ型イラプラゾールの固体形
TWI684449B (zh) 結晶型ＡＲＢ-ＮＥＰｉ複合物及其製備方法和應用
WO2016051393A2 (en) Crystalline form iv of trisodium supramolecular complex comprising valsartan and ahu-377 and methods thereof
US20220356319A1 (en) Sulcardine salts
JP2026512051A (ja) ベンズイミダゾール誘導体の塩
ES2463190B1 (es) Formas cristalinas de sartanes tales como telmisartán con betabloqueantes
JP5888612B2 (ja) 縮合ピリジン化合物塩の結晶
WO2025124537A1 (en) Integrin inhibitor and uses thereof
JP7357634B2 (ja) Ｕｒａｔ－１阻害剤の新規塩型
JP6357100B2 (ja) ６−（ピペリジン−４−イルオキシ）−２ｈ−イソキノリン−１−オン塩酸塩の結晶性溶媒和物
CN105693699A (zh) 托吡司他的新晶型及其制备方法
JP7604387B2 (ja) ベンゾチアゾール化合物の薬学的塩、多形体及びその製造方法
CA3288417A1 (en) Salt of benzimidazole derivative

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250821

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260113